Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A

• Main Authors: Kelong Han (Author), L Claret (Author), Y Piao (Author), P Hegde (Author), A Joshi (Author), JR Powell (Author), J Jin (Author), R Bruno (Author)
• Format: Book
• Published: Wiley, 2016-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

To simulate clinical trials to assess overall survival (OS) benefit of bevacizumab in combination with chemotherapy in selected patients with gastric cancer (GC), a modeling framework linking OS with tumor growth inhibition (TGI) metrics and baseline patient characteristics was developed. Various TG...